Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07661095 · ClinicalTrials.gov registry record · Phase 1
A Study of CRD3874-SI in People With Leukemia
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07661095: Recruiting Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07661095 is a Phase 1 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07661095, a Phase 1 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
Interventions
- DRUG CRD3874-SI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2028-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07661095
The ClinicalTrials.gov registry entry for NCT07661095 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CRD3874-SI is the first listed.
NCT07661095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07661095 about?
NCT07661095 is a clinical study titled "A Study of CRD3874-SI in People With Leukemia". The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
What is the current status of trial NCT07661095?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-06-15. Estimated completion is 2028-06-15.
What interventions are being tested in trial NCT07661095?
The interventions under investigation include: CRD3874-SI (DRUG).
Who is sponsoring clinical trial NCT07661095?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.